These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 31316523)
41. TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy. Williams C; Phillips A; Aggarwal V; Slonim LB; Fajgenbaum DC; Karmali R Case Rep Oncol; 2021; 14(3):1359-1365. PubMed ID: 34720942 [TBL] [Abstract][Full Text] [Related]
42. Increase in Vascular Endothelial Growth Factor (VEGF) Expression and the Pathogenesis of iMCD-TAFRO. Srkalovic G; Nijim S; Srkalovic MB; Fajgenbaum D Biomedicines; 2024 Jun; 12(6):. PubMed ID: 38927535 [TBL] [Abstract][Full Text] [Related]
43. Case Report: A case of TAFRO syndrome with severe and prolonged thrombocytopenia: diagnostic pitfalls. Sato H; Kanno A; Sato M; Endo A; Ito H; Ohara T; Shirota Y; Sumitomo K; Mori T; Furukawa K Front Immunol; 2023; 14():1266187. PubMed ID: 37901232 [TBL] [Abstract][Full Text] [Related]
44. Membranoproliferative glomerulonephritis associated with multicentric angiofollicular lymph node hyperplasia. Case report and review of the literature. Said R; Tarawneh M Am J Nephrol; 1992; 12(6):466-70. PubMed ID: 1292348 [TBL] [Abstract][Full Text] [Related]
45. Comparison of the clinical characteristics of TAFRO syndrome and idiopathic multicentric Castleman disease in general internal medicine: a 6-year retrospective study. Nishimura Y; Hanayama Y; Fujii N; Kondo E; Otsuka F Intern Med J; 2020 Feb; 50(2):184-191. PubMed ID: 31211492 [TBL] [Abstract][Full Text] [Related]
46. Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome. Iwaki N; Gion Y; Kondo E; Kawano M; Masunari T; Moro H; Nikkuni K; Takai K; Hagihara M; Hashimoto Y; Yokota K; Okamoto M; Nakao S; Yoshino T; Sato Y Sci Rep; 2017 Feb; 7():42316. PubMed ID: 28205564 [TBL] [Abstract][Full Text] [Related]
47. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy. Pfister F; Amann K; Daniel C; Klewer M; Büttner A; Büttner-Herold M Histopathology; 2018 Dec; 73(6):990-1001. PubMed ID: 30014486 [TBL] [Abstract][Full Text] [Related]
48. Renal histology in a patient with TAFRO syndrome: a case report. Mizuno H; Sekine A; Oguro M; Oshima Y; Kawada M; Sumida K; Yamanouchi M; Hayami N; Suwabe T; Hiramatsu R; Hasegawa E; Hoshino J; Sawa N; Fujii T; Takaichi K; Ohashi K; Ubara Y Hum Pathol; 2018 Dec; 82():258-263. PubMed ID: 29626596 [TBL] [Abstract][Full Text] [Related]
49. Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort. Maisonobe L; Bertinchamp R; Damian L; Gérard L; Berisha M; Guillet S; Fieschi C; Malphettes M; Fadlallah J; Hié M; Dunogué B; De Wilde V; Vandergheynst F; Zafrani L; Grall M; Saada N; Garzaro M; Oksenhendler E; Galicier L; Boutboul D Br J Haematol; 2022 Feb; 196(3):599-605. PubMed ID: 34585382 [TBL] [Abstract][Full Text] [Related]
50. To and TAFRO - a cryptic cause of acute renal failure: a case report. Shah N; Davidson T; Cheung C; Keung K BMC Nephrol; 2022 Jan; 23(1):19. PubMed ID: 34991522 [TBL] [Abstract][Full Text] [Related]
51. Cyclosporine therapy could be considered for membranoproliferative glomerulonephritis with immunoglobulin A deposits: a case report. Hidaka Y; Tamura H; Furuie K; Kuraoka S; Nagata H; Nakazato H BMC Nephrol; 2022 Nov; 23(1):358. PubMed ID: 36344919 [TBL] [Abstract][Full Text] [Related]
52. Acute Kidney Injury Caused by TAFRO Syndrome in a Chinese Patient: Efficacy of Long-Term Corticosteroids Combined with Bortezomib and Cyclophosphamide. Xia P; Zhang L; Zou M; Zhang T; Li R; Shi X; Wang J; Qin Y; Li X; Li J; Chen L Kidney Blood Press Res; 2020; 45(4):623-630. PubMed ID: 32492687 [TBL] [Abstract][Full Text] [Related]
54. Intracranial Hemorrhage in a Patient with TAFRO Syndrome Treated with Cyclosporine A and Rituximab. Akagi Y; Kato T; Yamashita Y; Hosoi H; Murata S; Yamamoto S; Warigaya K; Nakao T; Murata S; Sonoki T; Tamura S Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577894 [TBL] [Abstract][Full Text] [Related]
55. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series. Lust H; Gong S; Remiker A; Rossoff J Pediatr Blood Cancer; 2021 Oct; 68(10):e29261. PubMed ID: 34302703 [TBL] [Abstract][Full Text] [Related]
56. Idiopathic multicentric Castleman disease-TAFRO after COVID-19: A case report. Shiina T; Yamamoto EK; Yamada H; Sendo S; Kanzawa M; Saegusa J Mod Rheumatol Case Rep; 2024 Aug; ():. PubMed ID: 39177383 [TBL] [Abstract][Full Text] [Related]
57. Case report and literature review: Glomerular and neurologic thrombotic microangiopathy as a primary manifestation of multicentric castleman disease. Flahault A; Vignon M; Rabant M; Hummel A; Noël LH; Canioni D; Knebelmann B; Suarez F; El Karoui K Medicine (Baltimore); 2016 Oct; 95(41):e5047. PubMed ID: 27741115 [TBL] [Abstract][Full Text] [Related]
58. Two cases of idiopathic steroid-resistant nephrotic syndrome complicated with thrombotic microangiopathy. Nishi K; Sato M; Ogura M; Okutsu M; Ishikura K; Kamei K BMC Nephrol; 2020 Aug; 21(1):323. PubMed ID: 32746791 [TBL] [Abstract][Full Text] [Related]
59. Peculiar hyper vascular manifestations in idiopathic multicentric castleman disease without tafro syndrome: a case report. Jilani RK; Saleem MR; Akhtar S; Jawad W Ann Hematol; 2024 Oct; ():. PubMed ID: 39400742 [TBL] [Abstract][Full Text] [Related]